Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results
Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results
• Q2 Diluted EPS of $0.53; Adjusted Diluted EPS of $1.13, compared to prior year Adjusted Diluted EPS of $1.07
• The Breathe Right ® portfolio and LaCorium acquisitions performed as expected in first full quarter of ownership
• Adjusting guidance outlook range to $1,280 to $1,290 million in revenue, $4.48 to $4.55 in Adjusted Diluted EPS
TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-November 5, 2026-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first half fiscal 2027 ended September 30, 2026.
“We were pleased with our second quarter and first half revenue and EPS performance, driven by continued strength in our leading brands and strong early contributions from the Breathe Right ® portfolio and LaCorium acquisitions that closed in June and July, respectively. Our portfolio performed in line with our expectations, with strong consumption growth across channels including eCommerce. This translated into strong mid-single-digit earnings growth and sets us up for continued strong free cash flow moving forward,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.
Reported revenues in the second quarter of fiscal 2027 of $336.3 million increased 22.7% from $274.1 million in the second quarter of fiscal 2026, but decreased 1.6% excluding the impacts of foreign currency and a $65.1 million contribution from the acquisition of the Breathe Right® portfolio and LaCorium. The organic revenue performance versus the prior year comparable period reflected the expected headwind associated with order timing in Q1 and a decline in Clear Eyes®.
Reported net income for the second quarter of fiscal 2027 totaled $25.3 million, or $0.53 in diluted earnings per share, compared to $42.2 million, or $0.86 in diluted earnings per share, for the comparable period of fiscal 2026. On an adjusted non-GAAP basis, second quarter fiscal 2027 net income totaled $53.8 million, or $1.13 in diluted earnings per share, versus $52.5 million in net income and $1.07 in diluted earnings per share in the prior year comparable period.
Adjustments to net income in the second quarter of fiscal 2027 included certain costs associated with acquisitions including integration, transition, purchase accounting, legal and various other costs, such as costs associated with improving and optimizing the acquired Pillar5 facility for increases in long- term capacity, a loss on extinguishment of debt, associated tax adjustments and a normalized tax adjustment pertaining to the establishment of a valuation allowance against deferred tax assets. The adjustment to the second quarter of fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable presence in a new state.
Reported revenues for the first six months of fiscal 2027 totaled $602.0 million and compared to revenues of $523.6 million for the first six months of fiscal 2026. Revenues increased 15.0% versus the prior year comparable period and 0.7% excluding the impact of foreign currency and a $71.0 million contribution from the acquisition of the Breathe Right® portfolio and LaCorium. The organic revenue
increase for the first six months reflected increased demand across the broad portfolio which more than offset a decline in Clear Eyes®.
Reported net income for the first six months of fiscal 2027 totaled $54.5 million versus the prior year comparable period net income of $89.7 million. Non-GAAP adjusted net income for the first six months of fiscal 2027 totaled $100.3 million versus the prior year comparable period’s adjusted net income of $99.9 million. Diluted earnings per share were $1.14 for the first six months of fiscal 2027 compared to $1.81 per share in the prior year comparable period. Non-GAAP adjusted diluted earnings per share of $2.11 for the first six months of fiscal 2027 increased over the prior year comparable period’s adjusted diluted earnings per share of $2.02.
Adjustments to net income in the first six months of fiscal 2027 included certain costs associated with acquisitions including integration, transition, purchase accounting, legal and various other costs, such as costs associated with improving and optimizing the acquired Pillar5 facility for increases in long-term capacity, as well as a loss on extinguishment of debt, associated tax adjustments, and a normalized tax adjustment pertaining to the establishment of a valuation allowance against deferred tax assets. The adjustment to the first six months of fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable presence in a new state.
The Company's net cash provided by operating activities for the first six months of fiscal 2027 was $108.7 million, compared to $136.5 million during the prior year comparable period. Non-GAAP adjusted free cash flow in the first six months of fiscal 2027 was $123.0 million compared to $133.6 million in the prior year comparable period.
The Company's net debt position as of September 30, 2026 was approximately $2 billion. On July 15, 2026, the Company issued $400 million of new 6.25% senior notes due July 2034, which replaced the same principal of senior notes previously due in fiscal 2028.
North American OTC Healthcare : Segment revenues of $271.8 million for the second quarter fiscal 2027 increased 17.8% compared to the prior year comparable quarter's segment revenues of $230.8 million. The revenue increase was driven by a $47.5 million contribution from the acquisitions of the Breathe Right ® portfolio and LaCorium, partially offset by lower base business sales associated with accelerated order timing in first quarter fiscal 2027.
For the first six months of the current fiscal year, reported revenues for the North American OTC segment were $498.0 million, which compared to $443.3 million in the prior year comparable period.
The revenue increase was primarily driven by a $52.0 million contribution from the acquisitions of the Breathe Right ® portfolio and LaCorium, as well as higher CompoundW ® and TheraTears ® sales.
International OTC Healthcare : Fiscal second quarter 2027 segment revenues of $64.5 million increased 48.7% compared to $43.4 million reported in the prior year comparable period. The revenue performance was primarily driven by a $17.6 million contribution from the acquisitions of the Breathe Right ® portfolio and LaCorium, as well as double-digit sales growth for Hydralyte ® .
For the first six months of the current fiscal year, reported revenues for the International OTC Healthcare segment were $104.0 million, an increase of approximately 30% over the prior year comparable period’s revenues of $80.3 million. Strong revenue growth was primarily driven by a $19.0
million contribution from the acquisitions of the Breathe Right ® portfolio and LaCorium, as well as continued growth for Hydralyte ®.
Ron Lombardi, Chief Executive Officer, stated, "We are updating our fiscal 2027 outlook for revenues to $1,280 million to $1,290 million and adjusted diluted EPS of $4.48 to $4.55 primarily to reflect recent variability in Clear Eyes® production at Pillar5, which is expected to reduce product availability and revenue in the second half. While supply remains limited for Clear Eyes®, we continue to invest in our Pillar5 production site with the intent of delivering consistent quality output that generates long-term growth for the brand."
"It's important to note that our outlook for the remainder of the portfolio is unchanged, with the base business delivering growth and our recent acquisitions on track to deliver sales and profit consistent with our prior guidance. Against a challenging consumer environment, this is a testament to our trusted brands and diversified business model."
“We remain confident in our business, the strategic investments we have made over the past twelve months, and our medium-term outlook for approximately 10% annual revenue growth, approximately 8% annual EPS growth, and nearly $900 million of aggregate free cash flow over the next three years. The acquisitions of Breathe Right® and LaCorium provide attractive long-term growth opportunities as we integrate these brands into our portfolio. The acquisition of Pillar5 will provide vertical integration of our eye care supply chain and an important platform for continued investment in capacity, reliability and long-term growth. Together, these investments further strengthen our diversified portfolio and financial profile while supporting strong free cash flow, debt reduction and future capital deployment,” Mr. Lombardi concluded.
Previous Fiscal 2027 Current Fiscal 2027 Outlook Outlook Revenue $1,290 to $1,315 $1,280 to $1,290 million million Organic Revenue Growth +1.0% to +3.0% ~ Flat Adjusted Diluted $4.55 to $4.65 $4.48 to $4.55 E.P.S. Adjusted Free Cash $270 million or more $265 million or more Flow
Second Quarter Fiscal 2027 Conference Call, Accompanying Slide Presentation and Replay
The Company will host a conference call to review its second quarter and first half fiscal 2027 results today, November 5, 2026 at 8:30 a.m. ET. The Company provides a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at http://www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. The slide presentation can be accessed from the Investor Relations page of the Company’s website by clicking on Webcasts and Presentations.
A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.
In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.
This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "guidance," "outlook," "may," "will," "would," “believe,” “set up,” "expect," “on track,” "anticipate,” “positioned,” or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the Company's future operating results including revenues, organic growth, adjusted diluted earnings per share, and adjusted free cash flow; supply of Clear Eyes® and return to category leadership; the expected impact of Breathe Right® and LaCorium Health acquisitions on the Company’s sales and profit; the Company’s ability to rapidly reduce debt; and the Company’s ability to manage through the current environment through its business strategy and diverse product portfolio. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of business and economic conditions, including as a result of evolving U.S. and international tariffs, labor shortages, inflation and geopolitical instability, consumer trends, the impact of the Company’s advertising and marketing and new product development initiatives, customer inventory management initiatives and ordering patterns, fluctuating foreign exchange rates, competitive pressures, and the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption as a result of labor shortages. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic reports filed with the Securities and Exchange Commission.
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading consumer healthcare company growing trusted, category-defining brands. Headquartered in New York, the Company markets, sells, manufactures and distributes its products across the U.S., Canada, Australia, and select other international markets. Its diverse portfolio of iconic brands includes Breathe Right®, Monistat®, Summer's Eve®, BC®, Goody's®, Dramamine®, Fleet®, Hydralyte®, Gaviscon®, DenTek®, TheraTears®, Clear Eyes®, Compound W®, Dermal Therapy®, Chloraseptic®, Luden's®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, and Debrox®, among others. Learn more at www.prestigeconsumerhealthcare.com.
September 30, (In thousands) 2026 March 31, 2026 ────────────────────────────────────────────────────────────────────────────── Assets Current assets Cash and cash $ 46,515 $ 63,868 equivalents Accounts receivable, net of allowance of 244,124 191,920 $24,135 and $18,187, respectively Inventories 179,203 159,132 Prepaid expenses and other current 22,286 16,564 assets Total current 492,128 431,484 assets Property, plant and equipment, 116,868 121,689 net Operating lease right-of-use 24,621 27,780 assets Finance lease right-of-use 20,136 21,776 assets, net Goodwill 705,264 581,109 Intangible 3,357,059 2,299,605 assets, net Other long-term 5,585 10,870 assets Total Assets $ 4,721,661 $ 3,494,313 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 44,020 $ 22,791 Accrued interest 16,528 15,578 payable Operating lease liabilities, 7,218 6,910 current portion Finance lease liabilities, 2,743 2,656 current portion Other accrued 97,994 72,989 liabilities Total current 168,503 120,924 liabilities Long-term debt, 2,079,324 993,953 net Deferred income 489,533 447,417 tax liabilities Long-term operating lease liabilities, 17,509 20,955 net of current portion Long-term finance lease liabilities, net 16,576 17,968 of current portion Other long-term 5,551 5,580 liabilities Total Liabilities 2,776,996 1,606,797 Total Stockholders' 1,944,665 1,887,516 Equity Total Liabilities and Stockholders' $ 4,721,661 $ 3,494,313 Equity
Six Months Ended (In thousands) September 30, Operating Activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 54,472 $ 89,677 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 20,717 15,329 amortization Loss on disposal of property and 333 131 equipment Deferred and other 15,460 23,211 income taxes Amortization of debt 2,109 889 origination costs Amortization of acquired inventory 17,207 — step-up Stock-based 5,225 5,449 compensation costs Loss on extinguishment of 1,360 — debt Non-cash operating 4,192 3,879 lease cost Changes in operating assets and liabilities, net of the effects of acquisitions:
Accounts receivable -45,392 -2,580 Inventories 3,566 -10,277 Prepaid expenses and other current -6,181 -11,767 assets Accounts payable 16,023 22,545 Accrued liabilities 24,003 3,923 Operating lease -4,185 -3,839 liabilities Other -256 -71 Net cash provided by operating 108,653 136,499 activities Investing Activities Purchases of property, plant and -7,327 -2,940 equipment Acquisitions, net of -1,193,557 — cash acquired Other -1,757 -1,927 Net cash (used in) -1,202,641 -4,867 investing activities Financing Activities Proceeds from 1,140,000 — issuance of Term Loan Net increase in line 887 — of credit Term loan repayments -30,000 — Proceeds from issuance of senior 400,000 — notes Repayment of senior -400,000 — notes Payments of debt -28,829 — issuance costs Payments of finance -1,231 -1,147 leases Proceeds from exercise of stock 94 3,907 options Fair value of shares surrendered as -2,684 -4,216 payment of tax withholding Repurchase of common — -109,775 stock Other -1,486 — Net cash provided by (used in) financing 1,076,751 -111,231 activities Effects of exchange rate changes on cash -116 821 and cash equivalents (Decrease) increase in cash and cash -17,353 21,222 equivalents Cash and cash equivalents - 63,868 97,884 beginning of period Cash and cash equivalents - end of $ 46,515 $ 119,106 period Interest paid $ 41,124 $ 21,879 Income taxes paid $ 24,027 $ 25,088
*Intersegment revenues of $0.9 million were eliminated from the North American OTC Healthcare segment.
*Intersegment revenues of $1.6 million were eliminated from the North American OTC Healthcare segment.
*Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.
* Intersegment revenues of $1.2 million were eliminated from the North American OTC Healthcare segment.
In addition to financial results reported in accordance with GAAP, we disclose certain Non-GAAP financial measures ("NGFMs"), including, but not limited to, Non-GAAP Organic Revenues, Non-GAAP Organic Revenue Change Percentage, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense Percentage, Non-GAAP EBITDA, Non-GAAP EBITDA Margin, Non- GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted Diluted EPS, Non-GAAP Free Cash Flow, Non-GAAP Adjusted Free Cash Flow, and Net Debt. We use these NGFMs internally, along with GAAP information, in evaluating our operating performance and in making financial and operational decisions. We believe that the presentation of these NGFMs provides investors with greater transparency, and provides a more complete understanding of our business than could be obtained absent these disclosures, because the supplemental data relating to our financial condition and results of operations provides additional ways to view our operation when considered with both our GAAP results and the reconciliations below. In addition, we believe that the presentation of each of these NGFMs is useful to investors for period- to-period comparisons of results in assessing shareholder value, and we use these NGFMs internally to evaluate the performance of our personnel and also to evaluate our operating performance and compare our performance to that of our competitors.
These NGFMs are not in accordance with GAAP, should not be considered as a measure of profitability or liquidity, and may not be directly comparable to similarly titled NGFMs reported by other companies. These NGFMs have limitations and they should not be considered in isolation from or as an alternative to their most closely related GAAP measures reconciled below. Investors should not rely on any single financial measure when evaluating our business. We recommend investors review the GAAP financial measures included in this earnings release. When viewed in conjunction with our GAAP results and the reconciliations below, we believe these NGFMs provide greater transparency and a more complete understanding of factors affecting our business than GAAP measures alone.
• Non-GAAP Organic Revenues : GAAP Total Revenues excluding revenues associated with acquisitions and the impact of foreign currency exchange rates in the periods presented.
• Non-GAAP Organic Revenue Change Percentage : Calculated as the change in Non- GAAP Organic Revenues from prior year divided by prior year Non-GAAP Organic Revenues.
• Non-GAAP Adjusted Gross Margin : GAAP Gross Profit minus amortization of inventory fair value step-up, acquired facility remediation, period overhead and idle capacity costs.
• Non-GAAP Adjusted Gross Margin Percentage : Calculated as Non-GAAP Adjusted Gross Margin divided by GAAP Total Revenues.
• Non-GAAP Adjusted General and Administrative Expense : GAAP General and Administrative expenses minus costs associated with acquisitions.
• Non-GAAP Adjusted General and Administrative Expense Percentage : Calculated as Non-GAAP Adjusted General and Administrative expense divided by GAAP Total Revenues.
• Non-GAAP EBITDA : GAAP Net Income before interest expense, net, provision for income taxes, and depreciation and amortization.
• Non-GAAP EBITDA Margin : Calculated as Non-GAAP EBITDA divided by GAAP Total Revenues.
• Non-GAAP Adjusted EBITDA: Non-GAAP EBITDA before amortization of inventory fair value step‑up, acquired facility remediation, period overhead and idle capacity costs, costs associated with acquisitions, and loss on extinguishment of debt.
• Non-GAAP Adjusted EBITDA Margin: Calculated as Non-GAAP adjusted EBITDA divided by GAAP Total Revenues.
• Non-GAAP Adjusted Net Income : GAAP Net Income before amortization of inventory fair value step-up, depreciation of idle assets during remediation period, acquired facility remediation, period overhead and idle capacity costs, costs associated with acquisitions in General and Administrative Expense, loss on extinguishment of debt, applicable tax impact associated with these items and normalized tax rate adjustments.
• Non-GAAP Adjusted Diluted EPS : Calculated as Non-GAAP Adjusted Net Income, divided by the diluted weighted average number of shares outstanding during the period.
• Non-GAAP Free Cash Flow : Calculated as GAAP Net cash provided by operating activities less cash paid for capital expenditures.
• Non-GAAP Adjusted Free Cash Flow: Non-GAAP free cash flow plus acquisition and other costs paid.
• Net Debt : Calculated as total principal amount of debt outstanding ($2,110,000 at September 30, 2026) less cash and cash equivalents ($46,515 at September 30, 2026). Amounts in thousands.
The following tables set forth the reconciliations of each of our NGFMs (other than Net Debt, which is reconciled above) to their most directly comparable financial measures presented in accordance with GAAP. Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related Non-GAAP Organic Revenue Change percentage:
(a) Revenues associated with our Breathe Right® portfolio and LaCorium Health acquisitions are excluded for purposes of calculating Non-GAAP organic revenues. These revenue adjustments relate to our North America and International OTC Healthcare segments. Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and related Non-GAAP Adjusted Gross Margin percentage:
(a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels. Reconciliation of GAAP General and Administrative Expense and related GAAP General and Administrative Expense percentage to Non-GAAP Adjusted General and Administrative expense and related Non-GAAP Adjusted General and Administrative Expense percentage:
(a) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees. Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:
(a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.
(b) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees. Reconciliation of GAAP Net Income and GAAP Diluted Earnings Per Share to Non- GAAP Adjusted Net Income and related Non-GAAP Adjusted Diluted Earnings Per Share:
(a) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating. Management believes this depreciation is not reflective of expected ongoing depreciation levels once the facility is fully remediated and operating at normal production levels.
(b) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.
(c) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.
(d) The income tax adjustments are determined using applicable rates in the taxing jurisdictions in which the above adjustments relate and includes both current and deferred income tax expense (benefit) based on the specific nature of specific Non-GAAP performance measure.
Note: Amounts may not add due to rounding. Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow and Non-GAAP Adjusted Free Cash Flow:
: Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Free Cash Flow
(In millions) ──────────────────────────────────────────────────────────── Projected FY'27 GAAP Net cash provided by $ 269 operating activities Additions to property and equipment for cash -26 Projected FY'27 Non-GAAP Free Cash Flow 243 Acquisition and other costs paid 22 Projected FY'27 Non-GAAP Adjusted Free Cash Flow $ 265
Reconciliation of Projected GAAP Diluted EPS to Projected Non-GAAP Adjusted Diluted EPS (a):
Low High ────────────────────────────────────────────────────────────────────────────── Projected FY'27 GAAP Diluted EPS $ 3.53 $ 3.60 Adjustments: Costs associated with Pillar5 manufacturing optimization and 0.30 0.30 integration Costs associated with acquisitions of 0.64 0.64 the Breathe Right® portfolio and LaCorium Health Loss on extinguishment of debt 0.03 0.03 Tax impact of adjustments and normalized -0.02 -0.02 tax rate adjustments Total adjustments $ 0.95 $ 0.95 Projected FY'27 Non-GAAP Adjusted $ 4.48 $ 4.55 Diluted EPS
(a) The above reconciliation of this forward-looking non-GAAP financial measure only includes adjustments for Q1 and Q2 2027 and does not include additional adjustments for the remainder of fiscal 2027. These future adjustments are highly uncertain, given the significant variability and difficulty in making accurate projections of the adjustments related to the Breathe Right® portfolio and LaCorium Health acquisitions and the costs associated with Pillar5 manufacturing optimization and integration. As a result, the Company is unable to quantify those future adjustments, which are likely significant, without unreasonable efforts.
Full text with the tables
Exhibit 99.1
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results
• Q2 Revenue of $336.3 million, up 22.7% versus prior year
• Q2 Diluted EPS of $0.53; Adjusted Diluted EPS of $1.13, compared to prior year
Adjusted Diluted EPS of $1.07
• The Breathe Right ® portfolio and LaCorium acquisitions performed as expected
in first full quarter of ownership
• Adjusting guidance outlook range to $1,280 to $1,290 million in revenue, $4.48
to $4.55 in Adjusted Diluted EPS
TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-November 5, 2026-- Prestige Consumer
Healthcare Inc. (NYSE:PBH) today reported financial results for its second
quarter and first half fiscal 2027 ended September 30, 2026.
“We were pleased with our second quarter and first half revenue and EPS
performance, driven by continued strength in our leading brands and strong early
contributions from the Breathe Right ® portfolio and LaCorium acquisitions that
closed in June and July, respectively. Our portfolio performed in line with our
expectations, with strong consumption growth across channels including
eCommerce. This translated into strong mid-single-digit earnings growth and sets
us up for continued strong free cash flow moving forward,” said Ron Lombardi,
Chief Executive Officer of Prestige Consumer Healthcare.
Second Fiscal Quarter Ended September 30, 2026
Reported revenues in the second quarter of fiscal 2027 of $336.3 million
increased 22.7% from $274.1 million in the second quarter of fiscal 2026, but
decreased 1.6% excluding the impacts of foreign currency and a $65.1 million
contribution from the acquisition of the Breathe Right® portfolio and LaCorium.
The organic revenue performance versus the prior year comparable period
reflected the expected headwind associated with order timing in Q1 and a decline
in Clear Eyes®.
Reported net income for the second quarter of fiscal 2027 totaled $25.3 million,
or $0.53 in diluted earnings per share, compared to $42.2 million, or $0.86 in
diluted earnings per share, for the comparable period of fiscal 2026. On an
adjusted non-GAAP basis, second quarter fiscal 2027 net income totaled $53.8
million, or $1.13 in diluted earnings per share, versus $52.5 million in net
income and $1.07 in diluted earnings per share in the prior year comparable
period.
Adjustments to net income in the second quarter of fiscal 2027 included certain
costs associated with acquisitions including integration, transition, purchase
accounting, legal and various other costs, such as costs associated with
improving and optimizing the acquired Pillar5 facility for increases in long-
term capacity, a loss on extinguishment of debt, associated tax adjustments and
a normalized tax adjustment pertaining to the establishment of a valuation
allowance against deferred tax assets. The adjustment to the second quarter of
fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable
presence in a new state.
Six Months Ended September 30, 2026
Reported revenues for the first six months of fiscal 2027 totaled $602.0 million
and compared to revenues of $523.6 million for the first six months of fiscal
2026. Revenues increased 15.0% versus the prior year comparable period and 0.7%
excluding the impact of foreign currency and a $71.0 million contribution from
the acquisition of the Breathe Right® portfolio and LaCorium. The organic
revenue
increase for the first six months reflected increased demand across the broad
portfolio which more than offset a decline in Clear Eyes®.
Reported net income for the first six months of fiscal 2027 totaled $54.5
million versus the prior year comparable period net income of $89.7 million.
Non-GAAP adjusted net income for the first six months of fiscal 2027 totaled
$100.3 million versus the prior year comparable period’s adjusted net income of
$99.9 million. Diluted earnings per share were $1.14 for the first six months of
fiscal 2027 compared to $1.81 per share in the prior year comparable period.
Non-GAAP adjusted diluted earnings per share of $2.11 for the first six months
of fiscal 2027 increased over the prior year comparable period’s adjusted
diluted earnings per share of $2.02.
Adjustments to net income in the first six months of fiscal 2027 included
certain costs associated with acquisitions including integration, transition,
purchase accounting, legal and various other costs, such as costs associated
with improving and optimizing the acquired Pillar5 facility for increases in
long-term capacity, as well as a loss on extinguishment of debt, associated tax
adjustments, and a normalized tax adjustment pertaining to the establishment of
a valuation allowance against deferred tax assets. The adjustment to the first
six months of fiscal 2026 relates to a discrete tax item pertaining to
establishing a taxable presence in a new state.
Free Cash Flow and Balance Sheet
The Company's net cash provided by operating activities for the first six months
of fiscal 2027 was $108.7 million, compared to $136.5 million during the prior
year comparable period. Non-GAAP adjusted free cash flow in the first six months
of fiscal 2027 was $123.0 million compared to $133.6 million in the prior year
comparable period.
The Company's net debt position as of September 30, 2026 was approximately $2
billion. On July 15, 2026, the Company issued $400 million of new 6.25% senior
notes due July 2034, which replaced the same principal of senior notes
previously due in fiscal 2028.
Segment Review
North American OTC Healthcare : Segment revenues of $271.8 million for the
second quarter fiscal 2027 increased 17.8% compared to the prior year comparable
quarter's segment revenues of $230.8 million. The revenue increase was driven by
a $47.5 million contribution from the acquisitions of the Breathe Right ®
portfolio and LaCorium, partially offset by lower base business sales associated
with accelerated order timing in first quarter fiscal 2027.
For the first six months of the current fiscal year, reported revenues for the
North American OTC segment were $498.0 million, which compared to $443.3 million
in the prior year comparable period.
The revenue increase was primarily driven by a $52.0 million contribution from
the acquisitions of the Breathe Right ® portfolio and LaCorium, as well as
higher CompoundW ® and TheraTears ® sales.
International OTC Healthcare : Fiscal second quarter 2027 segment revenues of
$64.5 million increased 48.7% compared to $43.4 million reported in the prior
year comparable period. The revenue performance was primarily driven by a $17.6
million contribution from the acquisitions of the Breathe Right ® portfolio and
LaCorium, as well as double-digit sales growth for Hydralyte ® .
For the first six months of the current fiscal year, reported revenues for the
International OTC Healthcare segment were $104.0 million, an increase of
approximately 30% over the prior year comparable period’s revenues of $80.3
million. Strong revenue growth was primarily driven by a $19.0
million contribution from the acquisitions of the Breathe Right ® portfolio and
LaCorium, as well as continued growth for Hydralyte ®.
Updated Fiscal 2027 Outlook
Ron Lombardi, Chief Executive Officer, stated, "We are updating our fiscal 2027
outlook for revenues to $1,280 million to $1,290 million and adjusted diluted
EPS of $4.48 to $4.55 primarily to reflect recent variability in Clear Eyes®
production at Pillar5, which is expected to reduce product availability and
revenue in the second half. While supply remains limited for Clear Eyes®, we
continue to invest in our Pillar5 production site with the intent of delivering
consistent quality output that generates long-term growth for the brand."
"It's important to note that our outlook for the remainder of the portfolio is
unchanged, with the base business delivering growth and our recent acquisitions
on track to deliver sales and profit consistent with our prior guidance. Against
a challenging consumer environment, this is a testament to our trusted brands
and diversified business model."
“We remain confident in our business, the strategic investments we have made
over the past twelve months, and our medium-term outlook for approximately 10%
annual revenue growth, approximately 8% annual EPS growth, and nearly $900
million of aggregate free cash flow over the next three years. The acquisitions
of Breathe Right® and LaCorium provide attractive long-term growth opportunities
as we integrate these brands into our portfolio. The acquisition of Pillar5 will
provide vertical integration of our eye care supply chain and an important
platform for continued investment in capacity, reliability and long-term growth.
Together, these investments further strengthen our diversified portfolio and
financial profile while supporting strong free cash flow, debt reduction and
future capital deployment,” Mr. Lombardi concluded.
Previous Fiscal 2027 Current Fiscal 2027
Outlook Outlook
Revenue $1,290 to $1,315 $1,280 to $1,290
million million
Organic Revenue Growth +1.0% to +3.0% ~ Flat
Adjusted Diluted $4.55 to $4.65 $4.48 to $4.55
E.P.S.
Adjusted Free Cash $270 million or more $265 million or more
Flow
Second Quarter Fiscal 2027 Conference Call, Accompanying Slide Presentation and
Replay
The Company will host a conference call to review its second quarter and first
half fiscal 2027 results today, November 5, 2026 at 8:30 a.m. ET. The Company
provides a live Internet webcast, a slide presentation to accompany the call, as
well as an archived replay, all of which can be accessed from the Investor
Relations page of the Company's website at
http://www.prestigeconsumerhealthcare.com. To participate in the conference call
via phone, participants may register for the call here to receive dial-in
details and a unique pin. While not required, it is recommended to join 10
minutes prior to the event start. The slide presentation can be accessed from
the Investor Relations page of the Company’s website by clicking on Webcasts and
Presentations.
A conference call replay will be available for approximately one week following
completion of the live call and can be accessed on the Company’s Investor
Relations page.
Non-GAAP and Other Financial Information
In addition to financial results reported in accordance with generally accepted
accounting principles (GAAP), we have provided certain non-GAAP financial
information in this release to aid investors in understanding the Company's
performance. Each non-GAAP financial measure is defined and reconciled to its
most closely related GAAP financial measure in the “About Non-GAAP Financial
Measures” section at the end of this earnings release.
Note Regarding Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of
the federal securities laws that are intended to qualify for the Safe Harbor
from liability established by the Private Securities Litigation Reform Act of
1995. "Forward-looking statements" generally can be identified by the use of
forward-looking terminology such as "guidance," "outlook," "may," "will,"
"would," “believe,” “set up,” "expect," “on track,” "anticipate,” “positioned,”
or "continue" (or the negative or other derivatives of each of these terms) or
similar terminology. The "forward-looking statements" include, without
limitation, statements regarding the Company's future operating results
including revenues, organic growth, adjusted diluted earnings per share, and
adjusted free cash flow; supply of Clear Eyes® and return to category
leadership; the expected impact of Breathe Right® and LaCorium Health
acquisitions on the Company’s sales and profit; the Company’s ability to rapidly
reduce debt; and the Company’s ability to manage through the current environment
through its business strategy and diverse product portfolio. These statements
are based on management's estimates and assumptions with respect to future
events and financial performance and are believed to be reasonable, though are
inherently uncertain and difficult to predict. Actual results could differ
materially from those expected as a result of a variety of factors, including
the impact of business and economic conditions, including as a result of
evolving U.S. and international tariffs, labor shortages, inflation and
geopolitical instability, consumer trends, the impact of the Company’s
advertising and marketing and new product development initiatives, customer
inventory management initiatives and ordering patterns, fluctuating foreign
exchange rates, competitive pressures, and the ability of the Company’s
manufacturing operations and third party manufacturers and logistics providers
and suppliers to meet demand for its products and to avoid inflationary cost
increases and disruption as a result of labor shortages. A discussion of other
factors that could cause results to vary is included in the Company's Annual
Report on Form 10-K for the year ended March 31, 2026 and other periodic reports
filed with the Securities and Exchange Commission.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading consumer healthcare
company growing trusted, category-defining brands. Headquartered in New York,
the Company markets, sells, manufactures and distributes its products across the
U.S., Canada, Australia, and select other international markets. Its diverse
portfolio of iconic brands includes Breathe Right®, Monistat®, Summer's Eve®,
BC®, Goody's®, Dramamine®, Fleet®, Hydralyte®, Gaviscon®, DenTek®, TheraTears®,
Clear Eyes®, Compound W®, Dermal Therapy®, Chloraseptic®, Luden's®, Little
Remedies®, Boudreaux's Butt Paste®, Nix®, and Debrox®, among others. Learn more
at www.prestigeconsumerhealthcare.com.
Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Income and Comprehensive Income
(Unaudited)
(In
thousa… Three Six
except Months Months
per Ended Ended
share Septemb… Septem…
data) 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Total $ 336,307 $ 274,114 $ 602,017 $ 523,644
Revenu…
Cost of
Sales
Cost of
sales 160,512 120,043 286,978 226,758
exclud…
deprec…
Cost of
sales 3,257 2,492 6,313 4,976
deprec…
Cost of 163,769 122,535 293,291 231,734
sales
Gross 172,538 151,579 308,726 291,910
profit
Operat…
Expens…
Advert…
and 52,226 38,701 86,894 73,638
market…
General
and 30,893 28,037 74,196 56,493
admini…
Deprec…
and 8,707 5,171 14,404 10,353
amorti…
Total
operat… 91,826 71,909 175,494 140,484
expens…
Operat… 80,712 79,670 133,232 151,426
income
Other
expense
Intere…
expens… 30,026 10,036 43,971 20,239
net
Loss on
exting… 1,360 — 1,360 —
of debt
Other
expens… 1,876 501 1,910 277
net
Total
other 33,262 10,537 47,241 20,516
expens…
net
Income
before 47,450 69,133 85,991 130,910
income
taxes
Provis…
for 22,155 26,922 31,519 41,233
income
taxes
Net $ 25,295 $ 42,211 $ 54,472 $ 89,677
income
Earnin…
per
share:
Basic $ 0.53 $ 0.86 $ 1.15 $ 1.82
Diluted $ 0.53 $ 0.86 $ 1.14 $ 1.81
Weight…
average
shares
outsta…
Basic 47,495 49,025 47,479 49,249
Diluted 47,593 49,264 47,599 49,547
Compre…
income,
net of
tax:
Curren…
transl… 1,352 655 42 6,059
adjust…
Total
other 1,352 655 42 6,059
compre…
income
Compre… $ 26,647 $ 42,866 $ 54,514 $ 95,736
income
Prestige Consumer Healthcare Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
September 30,
(In thousands) 2026 March 31, 2026
──────────────────────────────────────────────────────────────────────────────
Assets
Current assets
Cash and cash $ 46,515 $ 63,868
equivalents
Accounts
receivable, net
of allowance of 244,124 191,920
$24,135 and
$18,187,
respectively
Inventories 179,203 159,132
Prepaid expenses
and other current 22,286 16,564
assets
Total current 492,128 431,484
assets
Property, plant
and equipment, 116,868 121,689
net
Operating lease
right-of-use 24,621 27,780
assets
Finance lease
right-of-use 20,136 21,776
assets, net
Goodwill 705,264 581,109
Intangible 3,357,059 2,299,605
assets, net
Other long-term 5,585 10,870
assets
Total Assets $ 4,721,661 $ 3,494,313
Liabilities and
Stockholders'
Equity
Current
liabilities
Accounts payable $ 44,020 $ 22,791
Accrued interest 16,528 15,578
payable
Operating lease
liabilities, 7,218 6,910
current
portion
Finance lease
liabilities, 2,743 2,656
current
portion
Other accrued 97,994 72,989
liabilities
Total current 168,503 120,924
liabilities
Long-term debt, 2,079,324 993,953
net
Deferred income 489,533 447,417
tax liabilities
Long-term
operating lease
liabilities, 17,509 20,955
net of current
portion
Long-term finance
lease
liabilities, net 16,576 17,968
of current
portion
Other long-term 5,551 5,580
liabilities
Total Liabilities 2,776,996 1,606,797
Total
Stockholders' 1,944,665 1,887,516
Equity
Total Liabilities
and Stockholders' $ 4,721,661 $ 3,494,313
Equity
Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Six Months Ended
(In thousands) September 30,
Operating Activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 54,472 $ 89,677
Adjustments to
reconcile net income
to
net cash provided by
operating
activities:
Depreciation and 20,717 15,329
amortization
Loss on disposal of
property and 333 131
equipment
Deferred and other 15,460 23,211
income taxes
Amortization of debt 2,109 889
origination costs
Amortization of
acquired inventory 17,207 —
step-up
Stock-based 5,225 5,449
compensation costs
Loss on
extinguishment of 1,360 —
debt
Non-cash operating 4,192 3,879
lease cost
Changes in operating
assets and
liabilities, net of
the effects of
acquisitions:
Accounts receivable -45,392 -2,580
Inventories 3,566 -10,277
Prepaid expenses and
other current -6,181 -11,767
assets
Accounts payable 16,023 22,545
Accrued liabilities 24,003 3,923
Operating lease -4,185 -3,839
liabilities
Other -256 -71
Net cash provided by
operating 108,653 136,499
activities
Investing Activities
Purchases of
property, plant and -7,327 -2,940
equipment
Acquisitions, net of -1,193,557 —
cash acquired
Other -1,757 -1,927
Net cash (used in) -1,202,641 -4,867
investing activities
Financing Activities
Proceeds from 1,140,000 —
issuance of Term Loan
Net increase in line 887 —
of credit
Term loan repayments -30,000 —
Proceeds from
issuance of senior 400,000 —
notes
Repayment of senior -400,000 —
notes
Payments of debt -28,829 —
issuance costs
Payments of finance -1,231 -1,147
leases
Proceeds from
exercise of stock 94 3,907
options
Fair value of shares
surrendered as -2,684 -4,216
payment of tax
withholding
Repurchase of common — -109,775
stock
Other -1,486 —
Net cash provided by
(used in) financing 1,076,751 -111,231
activities
Effects of exchange
rate changes on cash -116 821
and cash equivalents
(Decrease) increase
in cash and cash -17,353 21,222
equivalents
Cash and cash
equivalents - 63,868 97,884
beginning of
period
Cash and cash
equivalents - end of $ 46,515 $ 119,106
period
Interest paid $ 41,124 $ 21,879
Income taxes paid $ 24,027 $ 25,088
Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Income
Business Segments
(Unaudited)
Three
Months
Ended
September
30, 2026
──────────────────────────────────────────────────────────────────────────────
North Internati…
(In American OTC Consolid…
thousand… OTC Healthcare
Healthcare
Total
segment $ 271,812 $ 64,495 $ 336,307
revenues*
Cost of 132,992 30,777 163,769
sales
Gross 138,820 33,718 172,538
profit
Advertis…
and 40,488 11,738 52,226
marketing
Contribu… $ 98,332 $ 21,980 $ 120,312
margin
Other
operating 39,600
expenses
Operating $ 80,712
income
*Intersegment revenues of $0.9 million were eliminated from the North American
OTC Healthcare segment.
Six
Months
Ended
September
30, 2026
──────────────────────────────────────────────────────────────────────────────
North Internati…
(In American OTC Consolid…
thousand… OTC Healthcare
Healthca…
Total
segment $ 498,018 $ 103,999 $ 602,017
revenues*
Cost of 243,257 50,034 293,291
sales
Gross 254,761 53,965 308,726
profit
Advertis…
and 69,418 17,476 86,894
marketing
Contribu… $ 185,343 $ 36,489 $ 221,832
margin
Other
operating 88,600
expenses
Operating $ 133,232
income
*Intersegment revenues of $1.6 million were eliminated from the North American
OTC Healthcare segment.
Three
Months
Ended
September
30, 2025
──────────────────────────────────────────────────────────────────────────────
North Internati…
(In American OTC Consolid…
thousand… OTC Healthcare
Healthcare
Total
segment $ 230,756 $ 43,358 $ 274,114
revenues*
Cost of 102,348 20,187 122,535
sales
Gross 128,408 23,171 151,579
profit
Advertis…
and 32,033 6,668 38,701
marketing
Contribu… $ 96,375 $ 16,503 $ 112,878
margin
Other
operating 33,208
expenses
Operating $ 79,670
income
*Intersegment revenues of $0.6 million were eliminated from the North American
OTC Healthcare segment.
Six Months
Ended
September
30, 2025
──────────────────────────────────────────────────────────────────────────────
North Internati…
(In American OTC Consolid…
thousand… OTC Healthcare
Healthcare
Total
segment $ 443,334 $ 80,310 $ 523,644
revenues*
Cost of 194,526 37,208 231,734
sales
Gross 248,808 43,102 291,910
profit
Advertis…
and 60,987 12,651 73,638
marketing
Contribu… $ 187,821 $ 30,451 $ 218,272
margin
Other
operating 66,846
expenses
Operating $ 151,426
income
* Intersegment revenues of $1.2 million were eliminated from the North American
OTC Healthcare segment.
About Non-GAAP Financial Measures
In addition to financial results reported in accordance with GAAP, we disclose
certain Non-GAAP financial measures ("NGFMs"), including, but not limited to,
Non-GAAP Organic Revenues, Non-GAAP Organic Revenue Change Percentage, Non-GAAP
Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP
Adjusted General and Administrative Expense, Non-GAAP Adjusted General and
Administrative Expense Percentage, Non-GAAP EBITDA, Non-GAAP EBITDA Margin, Non-
GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Net
Income, Non-GAAP Adjusted Diluted EPS, Non-GAAP Free Cash Flow, Non-GAAP
Adjusted Free Cash Flow, and Net Debt. We use these NGFMs internally, along with
GAAP information, in evaluating our operating performance and in making
financial and operational decisions. We believe that the presentation of these
NGFMs provides investors with greater transparency, and provides a more complete
understanding of our business than could be obtained absent these disclosures,
because the supplemental data relating to our financial condition and results of
operations provides additional ways to view our operation when considered with
both our GAAP results and the reconciliations below. In addition, we believe
that the presentation of each of these NGFMs is useful to investors for period-
to-period comparisons of results in assessing shareholder value, and we use
these NGFMs internally to evaluate the performance of our personnel and also to
evaluate our operating performance and compare our performance to that of our
competitors.
These NGFMs are not in accordance with GAAP, should not be considered as a
measure of profitability or liquidity, and may not be directly comparable to
similarly titled NGFMs reported by other companies. These NGFMs have limitations
and they should not be considered in isolation from or as an alternative to
their most closely related GAAP measures reconciled below. Investors should not
rely on any single financial measure when evaluating our business. We recommend
investors review the GAAP financial measures included in this earnings release.
When viewed in conjunction with our GAAP results and the reconciliations below,
we believe these NGFMs provide greater transparency and a more complete
understanding of factors affecting our business than GAAP measures alone.
NGFMs Defined
We define our NGFMs presented herein as follows:
• Non-GAAP Organic Revenues : GAAP Total Revenues excluding revenues associated
with acquisitions and the impact of foreign currency exchange rates in the
periods presented.
• Non-GAAP Organic Revenue Change Percentage : Calculated as the change in Non-
GAAP Organic Revenues from prior year divided by prior year Non-GAAP Organic
Revenues.
• Non-GAAP Adjusted Gross Margin : GAAP Gross Profit minus amortization of
inventory fair value step-up, acquired facility remediation, period overhead and
idle capacity costs.
• Non-GAAP Adjusted Gross Margin Percentage : Calculated as Non-GAAP Adjusted
Gross Margin divided by GAAP Total Revenues.
• Non-GAAP Adjusted General and Administrative Expense : GAAP General and
Administrative expenses minus costs associated with acquisitions.
• Non-GAAP Adjusted General and Administrative Expense Percentage : Calculated
as Non-GAAP Adjusted General and Administrative expense divided by GAAP Total
Revenues.
• Non-GAAP EBITDA : GAAP Net Income before interest expense, net, provision for
income taxes, and depreciation and amortization.
• Non-GAAP EBITDA Margin : Calculated as Non-GAAP EBITDA divided by GAAP Total
Revenues.
• Non-GAAP Adjusted EBITDA: Non-GAAP EBITDA before amortization of inventory
fair value step‑up, acquired facility remediation, period overhead and idle
capacity costs, costs associated with acquisitions, and loss on extinguishment
of debt.
• Non-GAAP Adjusted EBITDA Margin: Calculated as Non-GAAP adjusted EBITDA
divided by GAAP Total Revenues.
• Non-GAAP Adjusted Net Income : GAAP Net Income before amortization of
inventory fair value step-up, depreciation of idle assets during remediation
period, acquired facility remediation, period overhead and idle capacity costs,
costs associated with acquisitions in General and Administrative Expense, loss
on extinguishment of debt, applicable tax impact associated with these items and
normalized tax rate adjustments.
• Non-GAAP Adjusted Diluted EPS : Calculated as Non-GAAP Adjusted Net Income,
divided by the diluted weighted average number of shares outstanding during the
period.
• Non-GAAP Free Cash Flow : Calculated as GAAP Net cash provided by operating
activities less cash paid for capital expenditures.
• Non-GAAP Adjusted Free Cash Flow: Non-GAAP free cash flow plus acquisition and
other costs paid.
• Net Debt : Calculated as total principal amount of debt outstanding
($2,110,000 at September 30, 2026) less cash and cash equivalents ($46,515 at
September 30, 2026). Amounts in thousands.
The following tables set forth the reconciliations of each of our NGFMs (other
than Net Debt, which is reconciled above) to their most directly comparable
financial measures presented in accordance with GAAP.
Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related
Non-GAAP Organic Revenue Change percentage:
Three Six
Mont… Months
Ended Ended
Sept… Septe…
(In 30, 30,
thou… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
Total $ 336,3… $ 274,… $ 602,… $ 523,6…
Reve…
Reve… 22.7 % 15.0 %
Chan…
Adju…
Reve…
asso…
with -65,0… — -71,… —
acqu…
(a)
Impa…
of
fore… — 1,530 — 3,616
curr…
exch…
rates
Total -65,0… 1,530 -71,… 3,616
adju…
Non-…
Orga… $ 271,2… $ 275,… $ 530,… $ 527,2…
Reve…
Non-…
Orga… -1.6 % 0.7 %
Reve…
Chan…
(a) Revenues associated with our Breathe Right® portfolio and LaCorium Health
acquisitions are excluded for purposes of calculating Non-GAAP organic revenues.
These revenue adjustments relate to our North America and International OTC
Healthcare segments.
Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and
related Non-GAAP Adjusted Gross Margin percentage:
Three Six
Mont… Mon…
Ended End…
Sept… Sep…
(In 30, 30,
tho… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
Tot… $ 336,… $ 274,… $ 602,… $ 523…
Rev…
GAAP
Gro… $ 172,… $ 151,… $ 308,… $ 291…
Pro…
GAAP
Gro…
Pro…
as a
Per… 51.3 % 55.3 % 51.3 % 55.7 %
of
GAAP
Tot…
Rev…
Adj…
Amo…
of
inv… 14,3… — 17,2… —
fair
val…
ste…
Acq…
fac…
rem…
per…
ove… 7,079 — 14,2… —
and
idle
cap…
cos…
(a)
Tot… 21,4… — 31,4… —
adj…
Non…
Adj… $ 193,… $ 151,… $ 340,… $ 291…
Gro…
Mar…
Non…
Adj…
Gro…
Mar…
as a 57.7 % 55.3 % 56.5 % 55.7 %
Per…
of
GAAP
Tot…
Rev…
(a) Represents manufacturing and administrative overhead incurred during a
remediation period following the acquisition of Pillar5, during which production
was significantly constrained. As a result, normal overhead absorption levels
were not achieved, leading to elevated unit costs. Management believes these
costs are not indicative of the Company’s expected ongoing operating cost
structure once the facility is fully remediated and operating at normal
production levels.
Reconciliation of GAAP General and Administrative Expense and related GAAP
General and Administrative Expense percentage to Non-GAAP Adjusted General and
Administrative expense and related Non-GAAP Adjusted General and Administrative
Expense percentage:
Three Six
Mont… Mont…
Ended Ended
Sept… Sept…
(In 30, 30,
tho… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
Gen…
and $ 30,8… $ 28,… $ 74,… $ 56,4…
Adm…
Exp…
GAAP
Gen…
and
Adm…
Exp…
as a 9.2 % 10.2 % 12.3 % 10.8 %
Per…
of
GAAP
Tot…
Rev…
Adj…
Cos…
ass…
with 722 — 13,… —
acq…
(a)
Tot… 722 — 13,… —
adj…
Non…
Adj…
Gen… $ 30,1… $ 28,… $ 60,… $ 56,4…
and
Adm…
Exp…
Non…
Adj…
Gen…
and
Adm…
Exp…
Per… 9.0 % 10.2 % 10.1 % 10.8 %
as a
Per…
of
GAAP
Tot…
Rev…
(a) Costs related to the consummation of the acquisition process such as legal
and other acquisition-related professional fees.
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA
Margin, Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:
Three Six
Mont… Mont…
Ended Ended
Sept… Sept…
(In 30, 30,
tho… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
Net $ 25,2… $ 42,… $ 54,… $ 89,6…
Inc…
Int…
exp… 30,0… 10,… 43,… 20,2…
net
Pro…
for 22,1… 26,… 31,… 41,2…
inc…
tax…
Dep…
and 11,9… 7,6… 20,… 15,3…
amo…
Non… $ 89,4… $ 86,… $ 150… $ 166,…
EBI…
Non…
EBI… 26.6 % 31.7 % 25.0 % 31.8 %
Mar…
Adj…
Amo…
of
inv… 14,3… — 17,… —
fair
val…
ste…
Acq…
fac…
rem…
per…
ove… 7,079 — 14,… —
and
idle
cap…
cos…
(a)
Cos…
ass…
with
acq… 722 — 13,… —
in
G&A
(b)
Loss
on
ext… 1,360 — 1,3… —
of
debt
Tot… 23,5… — 46,… —
adj…
Non…
Adj… $ 112,… $ 86,… $ 197… $ 166,…
EBI…
Non…
Adj… 33.6 % 31.7 % 32.7 % 31.8 %
EBI…
Mar…
(a) Represents manufacturing and administrative overhead incurred during a
remediation period following the acquisition of Pillar5, during which production
was significantly constrained. As a result, normal overhead absorption levels
were not achieved, leading to elevated unit costs. Management believes these
costs are not indicative of the Company’s expected ongoing operating cost
structure once the facility is fully remediated and operating at normal
production levels.
(b) Costs related to the consummation of the acquisition process such as legal
and other acquisition-related professional fees.
Reconciliation of GAAP Net Income and GAAP Diluted Earnings Per Share to Non-
GAAP Adjusted Net Income and related Non-GAAP Adjusted Diluted Earnings Per
Share:
… T… S…
… M… M…
… E… E…
… S… 2… 2… S… 2… 2…
… 3… D… D… 3… D… D…
… 2… E… 2… E… 2… E… 2… E…
──────────────────────────────────────────────────────────────────────────────
…
…
… 2… $ 0… 4… $ … … $ … … $ …
…
…
…
…
…
…
… 1… 0… — — … … — —
…
…
…
…
…
…
… 71 — — — … — — —
…
…
…
…
…
…
…
…
… 7… 0… — — … … — —
…
…
…
…
…
…
…
…
…
… 7… 0… — — … … — —
…
…
…
…
…
…
…
… 1… 0… — — … … — —
…
…
…
…
… -… -… — — … … — —
…
…
…
…
… 1… 0… 1… … … … … …
…
…
… 2… 0… 1… … … … … …
…
…
…
…
… $ 5… $ 1… $ 5… $ … $ … $ … $ … $ …
…
…
…
…
(a) Represents depreciation expense recorded during the remediation period
following the acquisition of Pillar5, during which certain production lines were
not operating. Management believes this depreciation is not reflective of
expected ongoing depreciation levels once the facility is fully remediated and
operating at normal production levels.
(b) Represents manufacturing and administrative overhead incurred during a
remediation period following the acquisition of Pillar5, during which production
was significantly constrained. As a result, normal overhead absorption levels
were not achieved, leading to elevated unit costs. Management believes these
costs are not indicative of the Company’s expected ongoing operating cost
structure once the facility is fully remediated and operating at normal
production levels.
(c) Costs related to the consummation of the acquisition process such as legal
and other acquisition-related professional fees.
(d) The income tax adjustments are determined using applicable rates in the
taxing jurisdictions in which the above adjustments relate and includes both
current and deferred income tax expense (benefit) based on the specific nature
of specific Non-GAAP performance measure.
(e) Income tax adjustments to adjust for discrete income tax items.
Note: Amounts may not add due to rounding.
Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow and Non-GAAP
Adjusted Free Cash Flow:
Three Six
Months Months
Ended Ended
Septem… Septe…
(In 30, 30,
thou… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
Net $ 25,295 $ 42,211 $ 54,472 $ 89,677
Inco…
Adju…
Adju…
to
reco…
net
inco…
to
net
cash
prov…
by 48,077 29,324 66,603 48,888
oper…
acti…
as
shown
in
the
Stat…
of
Cash
Flows
Chan…
in
oper…
asse…
and
liab…
net
of
effe…
of -35,5… -14,049 -12,422 -2,066
acqu…
as
shown
in
the
Stat…
of
Cash
Flows
Total 12,570 15,275 54,181 46,822
adju…
GAAP
Net
cash
prov… 37,865 57,486 108,653 136,4…
by
oper…
acti…
Purc…
of
prop… -3,624 -2,102 -7,327 -2,940
and
equi…
Non-…
Free 34,241 55,384 101,326 133,5…
Cash
Flow
Acqu…
and
other 5,000 — 21,664 —
costs
paid
Non-…
Adju…
Free $ 39,241 $ 55,384 $ 122,990 $ 133,5…
Cash
Flow
Outlook for Fiscal Year 2027
:
Reconciliation of Projected GAAP Net cash provided by operating activities to
Projected Non-GAAP Free Cash Flow
and Projected Non-GAAP Adjusted Free Cash Flow:
(In millions)
────────────────────────────────────────────────────────────
Projected FY'27 GAAP Net cash provided by $ 269
operating activities
Additions to property and equipment for cash -26
Projected FY'27 Non-GAAP Free Cash Flow 243
Acquisition and other costs paid 22
Projected FY'27 Non-GAAP Adjusted Free Cash Flow $ 265
Reconciliation of Projected GAAP Diluted EPS to Projected Non-GAAP Adjusted
Diluted EPS (a):
Low High
──────────────────────────────────────────────────────────────────────────────
Projected FY'27 GAAP Diluted EPS $ 3.53 $ 3.60
Adjustments:
Costs associated with Pillar5
manufacturing optimization and 0.30 0.30
integration
Costs associated with acquisitions
of 0.64 0.64
the Breathe Right® portfolio and
LaCorium Health
Loss on extinguishment of debt 0.03 0.03
Tax impact of adjustments and
normalized -0.02 -0.02
tax rate adjustments
Total adjustments $ 0.95 $ 0.95
Projected FY'27 Non-GAAP Adjusted $ 4.48 $ 4.55
Diluted EPS
(a) The above reconciliation of this forward-looking non-GAAP financial measure
only includes adjustments for Q1 and Q2 2027 and does not include additional
adjustments for the remainder of fiscal 2027. These future adjustments are
highly uncertain, given the significant variability and difficulty in making
accurate projections of the adjustments related to the Breathe Right® portfolio
and LaCorium Health acquisitions and the costs associated with Pillar5
manufacturing optimization and integration. As a result, the Company is unable
to quantify those future adjustments, which are likely significant, without
unreasonable efforts.